Abstract 954P
Background
The combination of PD-1 blockades with antiangiogenic drugs is the main therapeutic regimen for advanced hepatocellular carcinoma (HCC). Radiotherapy has generally been used to treat HCC with improved long-term outcome. The combination of radiotherapy and other therapies is considered to be a promising treatment for HCC. The objective of this study is to investigate the feasibility and safety of radiotherapy combined with tislelizumab plus anlotinib in advanced HCC.
Methods
In this single-center, open-label, phase II clinical trial, 45 patients(pts) with previously untreated, advanced HCC, with an age ranging from 18-75 years old, and an ECOG performance status ≤ 1 were planned to be enrolled. According to mRECIST efficacy evaluation criteria, the efficacy was evaluated by enhanced CT or MRI. RTOG/EORTC criteria was used to evaluate radiation-induced liver injury. Requirements for radiotherapy planning were D95% ≥14.2-46 Gy and ≥12.5-40 Gy for GTV and CTV, respectively. The patients underwent treatment with tislelizumab (200 mg, Q3W) plus anlotinib (8 mg, Q3W), and radiotherapy until disease progression or intolerance. The primary endpoints were ORR and OS, the secondary endpoints were PFS, DCR and safty.
Results
At data cut-off date of Feb 2023, 45 pts (44 males and 1 female) were enrolled with a median age of 51.5 years (range: 26-75). Of whom, 4 pts achieved complete response, 22 pts obtained partial response, 8 pts were stable disease, illustrating an ORR of 57.8% (95%CI 42.2-72.3) and a DCR of 75.6% (95%CI 60.5-87.1). The median PFS was 7.8 months (95%CI 5.8-9.8). The rate of treatment emerged adverse events (TEAEs) on grade 1/2 were 82.2%, and grade 3/4 were 13.3% (6/45). No grade 5 or radiation-induced liver disease were observed.
Conclusions
Radiotherapy combined with tislelizumab plus anlotinib demonstrated promising efficacy and tolerable safety profile in the treatment of advanced HCC. And this study was still ongoing and further follow-up was required to obtain final survival results subsequently.
Clinical trial identification
ChiCTR2000039022.
Editorial acknowledgement
Legal entity responsible for the study
the affiliated hospital of southwest medical university.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18